March 13, 2025 10:50 AM EDT

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Jaimy Lee

Deputy Editor

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Updated: White House pulls Weldon's nomination to lead CDC at last minute

MeiraGTx teams with cryptic AI startup, co-founded by Eric Schmidt, to advance Parkinson's gene therapy

Updated: Endo and Mallinckrodt to merge in $6.7B deal

Amgen reports more Uplizna data in myasthenia gravis ahead of FDA filing

Montara Therapeutics adds $20M to seed fundraise for neurology pipeline

Obesity drug development—still room to grow

Ace­lyrin, Pli­ant turn to ‘poi­son pill’ as Kevin Tang’s Con­cen­tra pur­sues both com­pa­nies

Deputy Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Acelyrin, Pliant turn to ‘poison pill’ as Kevin Tang’s Concentra pursues both companies